美国 · SEC FORM 4
SPRUCE BIOSCIENCES, INC.
SPRB · Nasdaq · CIK 0001683553 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
1 同一窗口内观察到的 Form 4 交易行
0 sales · 1 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-10-06 · Martinez Gregory; Parkman Healthcare Partners LLC.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 431,541
- 上期报告
- 416,140
- 日均成交量
- 95,333
- 回补天数
- 4.5
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-10-06 | Martinez Gregory; Parkman Healthcare Partners LLC | 买入 (P) | Common Stock, $0.001 par value per share | 256 | USD 17.91 | USD 4,585 | SEC 申报 ↗ |
| 2025-10-06 | Parkman Healthcare Partners LLC | 买入 (P) | Common Stock, $0.001 par value per share | 256 | USD 17.91 | USD 4,585 | SEC 申报 ↗ |
| 2023-02-16 | O'Donnell Niall | 买入 (P) | Common Stock | 630,400 | USD 3.17 | USD 1,998,368 | SEC 申报 ↗ |
| 2023-02-16 | Novo Holdings A/S | 买入 (P) | COMMON STOCK | 2,208,000 | USD 3.17 | USD 6,999,360 | SEC 申报 ↗ |
| 2020-10-14 | RiverVest Venture Fund III (Ohio), L.P.; RiverVest Venture Fund III, L.P.; RiverVest Venture Fund IV, L.P. | 买入 (P) | Common Stock | 250,000 | USD 15.00 | USD 3,750,000 | SEC 申报 ↗ |
| 2020-10-14 | Omega Fund VI GP Manager, Ltd.; Omega Fund VI GP, L.P.; Omega Fund VI, L.P. | 买入 (P) | Common Stock | 250,000 | USD 15.00 | USD 3,750,000 | SEC 申报 ↗ |
| 2020-10-14 | O'Donnell Niall | 买入 (P) | Common Stock | 250,000 | USD 15.00 | USD 3,750,000 | SEC 申报 ↗ |
| 2020-10-14 | Novo Holdings A/S | 买入 (P) | COMMON STOCK | 250,000 | USD 15.00 | USD 3,750,000 | SEC 申报 ↗ |
| 2020-10-14 | Muralidhar Bali | 买入 (P) | Common Stock | 200,000 | USD 15.00 | USD 3,000,000 | SEC 申报 ↗ |
| 2020-10-14 | HealthCap VIII, L.P. | 买入 (P) | Common Stock | 250,000 | USD 15.00 | USD 3,750,000 | SEC 申报 ↗ |
| 2020-10-14 | HANSSON JONAS | 买入 (P) | Common Stock | 250,000 | USD 15.00 | USD 3,750,000 | SEC 申报 ↗ |
| 2020-10-14 | Chaya Moghrabi Dina | 买入 (P) | Common Stock | 250,000 | USD 15.00 | USD 3,750,000 | SEC 申报 ↗ |
Form 4 申报证据
23 transaction lines in the latest 365-day window; 102 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | Szwarcberg Javier B. | 奖励／授予 (A) | Common Stock | 266 | USD 4.53 | USD 1,205 | SEC 申报 ↗ |
| 2025-12-31 | Szwarcberg Javier B. | 奖励／授予 (A) | Common Stock | 4,690 | USD 4.53 | USD 21,246 | SEC 申报 ↗ |
| 2025-12-15 | Szwarcberg Javier B. | 期权行权／转换 (M) | Common Stock | 2,676 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (19 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | Szwarcberg Javier B. | 奖励／授予 (A) | Common Stock | 266 | USD 4.53 | USD 1,205 | SEC 申报 ↗ |
| 2025-12-31 | Szwarcberg Javier B. | 奖励／授予 (A) | Common Stock | 4,690 | USD 4.53 | USD 21,246 | SEC 申报 ↗ |
| 2025-12-15 | Szwarcberg Javier B. | 期权行权／转换 (M) | Common Stock | 2,676 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-15 | Szwarcberg Javier B. | 代扣税 (F) | Common Stock | 1,360 | USD 80.67 | USD 109,711 | SEC 申报 ↗ |
| 2025-12-15 | Gharib Samir M. | 期权行权／转换 (M) | Common Stock | 1,009 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-15 | Gharib Samir M. | 代扣税 (F) | Common Stock | 362 | USD 80.67 | USD 29,203 | SEC 申报 ↗ |
| 2025-12-11 | Ways Douglas Kirk | 期权行权／转换 (M) | Common Stock | 1,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-11 | Szwarcberg Javier B. | 期权行权／转换 (M) | Common Stock | 4,950 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-11 | Szwarcberg Javier B. | 代扣税 (F) | Common Stock | 2,194 | USD 88.41 | USD 193,972 | SEC 申报 ↗ |
| 2025-12-11 | Gharib Samir M. | 期权行权／转换 (M) | Common Stock | 1,900 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-11 | Gharib Samir M. | 代扣税 (F) | Common Stock | 680 | USD 88.41 | USD 60,119 | SEC 申报 ↗ |
| 2025-12-10 | Szwarcberg Javier B. | 期权行权／转换 (M) | Common Stock | 1,196 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-10 | Szwarcberg Javier B. | 代扣税 (F) | Common Stock | 428 | USD 85.67 | USD 36,667 | SEC 申报 ↗ |
| 2025-12-10 | Gharib Samir M. | 期权行权／转换 (M) | Common Stock | 514 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-10 | Gharib Samir M. | 代扣税 (F) | Common Stock | 184 | USD 85.67 | USD 15,763 | SEC 申报 ↗ |
| 2025-10-20 | Szwarcberg Javier B. | 期权行权／转换 (M) | Common Stock | 4,784 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-10-20 | Szwarcberg Javier B. | 代扣税 (F) | Common Stock | 1,539 | USD 148.16 | USD 228,018 | SEC 申报 ↗ |
| 2025-10-20 | Gharib Samir M. | 期权行权／转换 (M) | Common Stock | 2,053 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-10-20 | Gharib Samir M. | 代扣税 (F) | Common Stock | 661 | USD 148.16 | USD 97,934 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | SPRB |
| CIK | 0001683553 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 102 transaction lines from 2020-10-14 to 2026-06-30 12 P purchase lines · 12 S sale lines · 78 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.